Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Piotr Smolewski & Tadeusz Robak. (2015) The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Drug Discovery 10:7, pages 791-808.
Read now
Read now
Srinivas Mamidi, Simon Höne, Claudia Teufel, Leopold Sellner, Thorsten Zenz & Michael Kirschfink. (2015) Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. OncoImmunology 4:3.
Read now
Read now
Christian H. Geisler, Tamar Tadmor & Aaron Polliack. (2015) Treating chronic lymphocytic leukemia with a combination of rituximab and alemtuzumab: a “successful couple,” but are they still relevant together?. Leukemia & Lymphoma 56:2, pages 275-276.
Read now
Read now
Saskia Meyer, Jeanette HW Leusen & Peter Boross. (2014) Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. mAbs 6:5, pages 1133-1144.
Read now
Read now
Mikołaj Słabicki & Thorsten Zenz. (2012) Improving treatment for chronic lymphocytic leukemia by rational use of monoclonal antibodies. Leukemia & Lymphoma 53:11, pages 2101-2102.
Read now
Read now
Articles from other publishers (31)
Yu Fan, Juan Liao, Yu Wang, Zhu Wang, Hong Zheng & Yanping Wang. (2023) miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55. Clinical and Experimental Immunology 211:1, pages 57-67.
Crossref
Crossref
Manh-Hung Do, Hien Duong Thanh, Phuong Kim To, Min Soo Kim, Changjong Moon & Chaeyong Jung. (2022) CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity. Scientific Reports 12:1.
Crossref
Crossref
Jutatip Panaampon, Ryusho Kariya & Seiji Okada. (2022) Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells. Cancer Immunology, Immunotherapy 71:10, pages 2497-2509.
Crossref
Crossref
Jutatip Panaampon, Ryusho Kariya & Seiji Okada. (2021) Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. Cancer Immunology, Immunotherapy 71:5, pages 1017-1031.
Crossref
Crossref
Yoonyoung Kim, Yu Seok Youn, Kyung Taek Oh, Dongin Kim & Eun Seong Lee. (2020) Tumor-Targeting Liposomes with Transient Holes Allowing Intact Rituximab Internally. Biomacromolecules 22:2, pages 723-731.
Crossref
Crossref
Brina Stančič, Bodil Qvarfordt, Magnus M. Berglund, Nina Brenden, Mona Sydow Bäckman, Moa Fransson, Sofia Nordling & Peetra U. Magnusson. (2021) The blood endothelial cell chamber – An innovative system to study immune responses in drug development. International Immunopharmacology 90, pages 107237.
Crossref
Crossref
Clive S. Zent, Jonathan J. Pinney, Charles C. Chu & Michael R. Elliott. (2020) Complement Activation in the Treatment of B-Cell Malignancies. Antibodies 9:4, pages 68.
Crossref
Crossref
Josée Golay & Ronald P. Taylor. (2020) The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies 9:4, pages 58.
Crossref
Crossref
Sagun Parakh, Dylan King, Hui K. Gan & Andrew M. Scott. 2020. Current Immunotherapeutic Strategies in Cancer. Current Immunotherapeutic Strategies in Cancer
1
70
.
Karl R. VanDerMeid, Michael R. Elliott, Andrea M. Baran, Paul M. Barr, Charles C. Chu & Clive S. Zent. (2018) Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. Cancer Immunology Research 6:10, pages 1150-1160.
Crossref
Crossref
Clive S. Zent. (2018) Monoclonal antibody therapy in chronic lymphocytic leukemia. Oncology Signaling 1:1, pages 11-13.
Crossref
Crossref
Erika A.K. Fletcher, Mohamed Eltahir, Frida Lindqvist, Jonas Rieth, Gunilla Törnqvist, Justyna Leja-Jarblad & Sara M. Mangsbo. (2018) Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics. International Immunopharmacology 54, pages 1-11.
Crossref
Crossref
Claire Dobson & William Dall'Acqua. 2017. Protein Therapeutics. Protein Therapeutics
189
227
.
Kristina M. Ilieva, Judit Fazekas-Singer, Daniela Y. Achkova, Tihomir S. Dodev, Silvia Mele, Silvia Crescioli, Heather J. Bax, Anthony Cheung, Panagiotis Karagiannis, Isabel Correa, Mariangela Figini, Rebecca Marlow, Debra H. Josephs, Andrew J. Beavil, John Maher, James F. Spicer, Erika Jensen-Jarolim, Andrew N. Tutt & Sophia N. Karagiannis. (2017) Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. Frontiers in Immunology 8.
Crossref
Crossref
Erika M. Cook, Margaret A. Lindorfer, Hilma van der Horst, Simone Oostindie, Frank J. Beurskens, Janine Schuurman, Clive S. Zent, Richard Burack, Paul W. H. I. Parren & Ronald P. Taylor. (2016) Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. The Journal of Immunology 197:5, pages 1762-1775.
Crossref
Crossref
Ronald P. Taylor & Margaret A. Lindorfer. (2016) Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Seminars in Immunology 28:3, pages 309-316.
Crossref
Crossref
Grzegorz Stasiłojć, Anders Österborg, Anna M. Blom & Marcin Okrój. (2016) New perspectives on complement mediated immunotherapy. Cancer Treatment Reviews 45, pages 68-75.
Crossref
Crossref
Emyr Bakker, Malak Qattan, Luciano Mutti, Constantinos Demonacos & Marija Krstic-Demonacos. (2016) The role of microenvironment and immunity in drug response in leukemia. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1863:3, pages 414-426.
Crossref
Crossref
Margaret A. Lindorfer, Erika M. Cook, Jillian C. Tupitza, Clive S. Zent, Richard Burack, Rob N. de Jong, Frank J. Beurskens, Janine Schuurman, Paul W.H.I. Parren & Ronald P. Taylor. (2016) Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. Molecular Immunology 70, pages 13-23.
Crossref
Crossref
A K Church, K R VanDerMeid, N A Baig, A M Baran, T E Witzig, G S Nowakowski & C S Zent. (2016) Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clinical and Experimental Immunology 183:1, pages 90-101.
Crossref
Crossref
Mohammad Hojjat-Farsangi, Mahmood Jeddi-Tehrani, Amir Hossein Daneshmanesh, Fariba Mozaffari, Ali Moshfegh, Lotta Hansson, Seyed Mohsen Razavi, Ramazan Ali Sharifian, Hodjattallah Rabbani, Anders Österborg, Håkan Mellstedt & Fazel Shokri. (2015) Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia. PLOS ONE 10:11, pages e0142310.
Crossref
Crossref
YI LU & XIAO-BO HU. (2014) C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation. Oncology Reports 32:6, pages 2817-2823.
Crossref
Crossref
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren & Ronald P. Taylor. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1733
1774
.
Laura M. Rogers, Suresh Veeramani & George J. Weiner. (2014) Complement in monoclonal antibody therapy of cancer. Immunologic Research 59:1-3, pages 203-210.
Crossref
Crossref
Clive S. Zent, Ronald P. Taylor, Margaret A. Lindorfer, Paul V. Beum, Betsy LaPlant, Wenting Wu, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Lori A. Frederick, Brian K. Link, Sue E. Blackwell, Suresh Veeramani, Nisar A. Baig, David S. Viswanatha, George J. Weiner & Thomas E. Witzig. (2014) Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. American Journal of Hematology 89:7, pages 757-765.
Crossref
Crossref
Nisar A. Baig, Ronald P. Taylor, Margaret A. Lindorfer, Amy K. Church, Betsy R. LaPlant, Adam M. Pettinger, Tait D. Shanafelt, Grzegorz S. Nowakowski & Clive S. Zent. (2014) Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia. The Journal of Immunology 192:4, pages 1620-1629.
Crossref
Crossref
Ronald P. Taylor & Margaret A. Lindorfer. (2014) The role of complement in mAb-based therapies of cancer. Methods 65:1, pages 18-27.
Crossref
Crossref
Giuseppe TridenteGiuseppe Tridente. 2014. Adverse Events with Biomedicines. Adverse Events with Biomedicines
281
289
.
Margaret Lindorfer, Paul Beum & Ronald Taylor. (2013) CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I. Antibodies 2:4, pages 598-616.
Crossref
Crossref
Stephanie Tung, Yonghong ShiKarry WongFang ZhuReg GorczynskiRobert C. LaisterMark MindenAnne-Kareen Blechert, Yvonne Genzel, Udo Reichl & David E. Spaner. (2013) PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood 122:6, pages 969-980.
Crossref
Crossref
Shundong Cang, Nikhil Mukhi, Kemeng Wang & Delong Liu. (2012) Novel CD20 monoclonal antibodies for lymphoma therapy. Journal of Hematology & Oncology 5:1.
Crossref
Crossref